Anavir Pharmaceuticals, a biotech company in the pharmaceuticals industry, is under scrutiny after a report in The Wall Street Journal showed that its stock price fell to a new low on Wednesday after the company’s chief executive officer, Andrew D. Dickson, resigned.
Mr. Dickson is the latest of a number of executives to resign at the company since the publication of the article.
Titan Pharmaceutical has been under pressure from investors and the news media over its financial performance and its lack of transparency regarding its stock trading.
In a statement, Mr. Vanneste, Titan’s chief financial officer, said the company would be “conducting a thorough internal review of all issues” as well as “working closely with the relevant regulatory authorities.”
Mr. J.P. Oltman, who joined Titan in June, said that his departure was due to “personal reasons.” Mr